PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus.

Abstract Recent publications describing long-term follow-up from landmark trials and diabetes registries represent an opportunity to revisit modeling options in type 1 diabetes mellitus (T1DM).
PMID
Related Publications

Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.

Validation of the CORE Diabetes Model against epidemiological and clinical studies.

Assessing the cost-effectiveness of type 1 diabetes interventions: the Sheffield type 1 diabetes policy model.

COST-EFFECTIVENESS OF STRUCTURED EDUCATION IN CHILDREN WITH TYPE-1 DIABETES MELLITUS.

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.

Authors

Mayor MeshTerms

Models, Economic

Models, Theoretical

Keywords

cost-effectiveness

model

risk prediction

type 1 diabetes mellitus

Journal Title value in health : the journal of the international society for pharmacoeconomics and outcomes research
Publication Year Start




PMID- 28712629
OWN - NLM
STAT- MEDLINE
DA  - 20170717
DCOM- 20170724
LR  - 20170724
IS  - 1524-4733 (Electronic)
IS  - 1098-3015 (Linking)
VI  - 20
IP  - 7
DP  - 2017 Jul - Aug
TI  - The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and
      Cost Outcomes in Type 1 Diabetes Mellitus.
PG  - 985-991
LID - S1098-3015(16)30089-4 [pii]
LID - 10.1016/j.jval.2016.12.001 [doi]
AB  - BACKGROUND: Recent publications describing long-term follow-up from landmark
      trials and diabetes registries represent an opportunity to revisit modeling
      options in type 1 diabetes mellitus (T1DM). OBJECTIVES: To develop a new
      product-independent model capable of predicting long-term clinical and cost
      outcomes. METHODS: After a systematic literature review to identify clinical
      trial and registry data, a model was developed (the PRIME Diabetes Model) to
      simulate T1DM progression and complication onset. The model runs as a
      patient-level simulation, making use of covariance matrices for cohort generation
      and risk factor progression, and simulating myocardial infarction, stroke,
      angina, heart failure, nephropathy, retinopathy, macular edema, neuropathy,
      amputation, hypoglycemia, ketoacidosis, mortality, and risk factor evolution.
      Several approaches novel to T1DM modeling were used, including patient
      characteristics and risk factor covariance, a glycated hemoglobin progression
      model derived from patient-level data, and model averaging approaches to evaluate
      complication risk. RESULTS: Validation analyses comparing modeled outcomes with
      published studies demonstrated that the PRIME Diabetes Model projects long-term
      patient outcomes consistent with those reported for a number of long-term
      studies. Macrovascular end points were reliably reproduced across five different 
      populations and microvascular complication risk was accurately predicted on the
      basis of comparisons with landmark studies and published registry data.
      CONCLUSIONS: The PRIME Diabetes Model is product-independent, available online,
      and has been developed in line with good practice guidelines. Validation has
      indicated that outcomes from long-term studies can be reliably reproduced. The
      model offers new approaches to long-standing challenges in diabetes modeling and 
      may become a valuable tool for informing health care policy.
CI  - Copyright (c) 2017 International Society for Pharmacoeconomics and Outcomes
      Research (ISPOR). Published by Elsevier Inc. All rights reserved.
FAU - Valentine, William J
AU  - Valentine WJ
AD  - Ossian Health Economics and Communications, Basel, Switzerland. Electronic
      address: [email protected]
FAU - Pollock, Richard F
AU  - Pollock RF
AD  - Ossian Health Economics and Communications, Basel, Switzerland.
FAU - Saunders, Rhodri
AU  - Saunders R
AD  - Ossian Health Economics and Communications, Basel, Switzerland.
FAU - Bae, Jay
AU  - Bae J
AD  - Eli Lilly and Company, Indianapolis, IN, USA.
FAU - Norrbacka, Kirsi
AU  - Norrbacka K
AD  - Eli Lilly and Company, Helsinki, Finland.
FAU - Boye, Kristina
AU  - Boye K
AD  - Eli Lilly and Company, Indianapolis, IN, USA.
LA  - eng
PT  - Journal Article
PT  - Validation Studies
DEP - 20170504
PL  - United States
TA  - Value Health
JT  - Value in health : the journal of the International Society for Pharmacoeconomics 
      and Outcomes Research
JID - 100883818
SB  - IM
MH  - Diabetes Mellitus, Type 1/economics/physiopathology/*therapy
MH  - Disease Progression
MH  - Female
MH  - Health Policy
MH  - Humans
MH  - Male
MH  - *Models, Economic
MH  - *Models, Theoretical
MH  - Outcome Assessment (Health Care)/*methods
MH  - Reproducibility of Results
MH  - Risk Factors
MH  - Time Factors
OTO - NOTNLM
OT  - cost-effectiveness
OT  - model
OT  - risk prediction
OT  - type 1 diabetes mellitus
EDAT- 2017/07/18 06:00
MHDA- 2017/07/25 06:00
CRDT- 2017/07/18 06:00
PHST- 2016/02/12 [received]
PHST- 2016/12/01 [accepted]
AID - S1098-3015(16)30089-4 [pii]
AID - 10.1016/j.jval.2016.12.001 [doi]
PST - ppublish
SO  - Value Health. 2017 Jul - Aug;20(7):985-991. doi: 10.1016/j.jval.2016.12.001. Epub
      2017 May 4.